Synergistic combinations
First Claim
Patent Images
1. A combination comprising a synergistic ratio of an alpha-2-delta ligand and a PDEV inhibitor, or a pharmaceutically acceptable salt or solvate of any thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The instant invention relates to a combination of an alpha-2-delta ligand and a PDEV inhibitor for use in therapy, particularly in the curative, prophylactic or palliative treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred PDEV inhibitors are sildenafil, vardenafil and tadalafil.
-
Citations
16 Claims
- 1. A combination comprising a synergistic ratio of an alpha-2-delta ligand and a PDEV inhibitor, or a pharmaceutically acceptable salt or solvate of any thereof.
-
11. A combination comprising an alpha-2-delta ligand, excluding gabapentin, pregabalin and compounds of formula (i)-(xxv) of PCT/IB02/01146 and a PDEV inhibitor.
-
15. A synergistic combination for human administration comprising an alpha-2-delta ligand and a PDEV inhibitor, or pharmaceutically acceptable salts or solvates thereof, in a w/w combination range which corresponds to a synergistic combination range of the order of 1:
- 1 to 10;
1 parts by weight in the rat model of CCI induced static allodynia.
- 1 to 10;
Specification